An update on DPP-4 inhibitors in the management of type 2 diabetes.
about
Do we know the true mechanism of action of the DPP-4 inhibitors?Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and highIn Silico Approaches Applied to the Study of Peptide Analogs of Ile-Pro-Ile in Relation to Their Dipeptidyl Peptidase IV Inhibitory Properties.
P2860
An update on DPP-4 inhibitors in the management of type 2 diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
An update on DPP-4 inhibitors in the management of type 2 diabetes.
@en
type
label
An update on DPP-4 inhibitors in the management of type 2 diabetes.
@en
prefLabel
An update on DPP-4 inhibitors in the management of type 2 diabetes.
@en
P2093
P2860
P1476
An update on DPP-4 inhibitors in the management of type 2 diabetes.
@en
P2093
Avivit Cahn
Itamar Raz
Simona Cernea
P2860
P304
P356
10.1080/14728214.2016.1257608
P407
P577
2016-11-04T00:00:00Z